Trial Profile
To evaluate the efficacy and safety of KP-496NS for patients with perennial allergic rhinitis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2009
Price :
$35
*
At a glance
- Drugs KP 496 (Primary)
- Indications Hypersensitivity; Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors Kaken Pharmaceutical
- 01 Apr 2009 New trial record.